| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alexander P Landry, Justin Z Wang, Vikas Patil, Jeff Liu, Chloe Gui, Yosef Ellenbogen, Andrew Ajisebutu, Leeor Yefet, Qingxia Wei, Olivia Singh, Julio Sosa, Sheila Mansouri, Aaron A Cohen-Gadol, Ghazaleh Tabatabai, Marcos Tatagiba, Felix Behling, Jill S Barnholtz-Sloan, Andrew E Sloan, Silky Chotai, Lola B Chambless, Alireza Mansouri, Serge Makarenko, Stephen Yip, Felix Ehret, David Capper, Derek S Tsang, Jennifer Moliterno, Murat Gunel, Pieter Wesseling, Felix Sahm, Kenneth Aldape, Andrew Gao, Gelareh Zadeh, Farshad Nassir. Chromosome 1p Loss and 1q Gain for Grading of Meningioma. JAMA oncology. 2025-04-03. PMID:40178835. |
the world health organization (who) classification of central nervous system tumors (cns) grading for meningioma was updated in 2021 to include rare molecular features, namely homozygous deletions of cdkn2a or cdkn2b and tert promotor alterations. |
2025-04-03 |
2025-04-04 |
Not clear |
| Hojka Rowbottom, Tomaž Šmigoc, Janez Ravni. Malignant Meningiomas: From Diagnostics to Treatment. Diagnostics (Basel, Switzerland). vol 15. issue 5. 2025-03-13. PMID:40075786. |
according to the latest world health organization (who) classification of tumors of the central nervous system (cns), grade 3 should be assigned based on criteria for anaplastic meningiomas, which comprise malignant cytomorphology (anaplasia) that resembles carcinoma, high-grade sarcoma or melanoma; elevated mitotic activity; a tert promoter mutation and/or a homozygous cdkn2a and/or cdkn2b deletion. |
2025-03-13 |
2025-03-15 |
Not clear |
| Felix Sahm, Kenneth D Aldape, Priscilla K Brastianos, Daniel J Brat, Sonika Dahiya, Andreas von Deimling, Caterina Giannini, Mark R Gilbert, David N Louis, David R Raleigh, Guido Reifenberger, Sandro Santagata, Chitra Sarkar, Gelareh Zadeh, Pieter Wesseling, Arie Perr. cIMPACT-NOW Update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas. Neuro-oncology. 2024-08-30. PMID:39212325. |
the 2021 who classification of central nervous system tumors ("cns5") has introduced the first molecular grading parameters for meningioma with oncogenic variants in the tert promoter and homozygous deletion of cdkn2a/b as markers for cns who grade 3. |
2024-08-30 |
2024-09-04 |
Not clear |
| Felix Ehret, Eilís Perez, Daniel Teichmann, Sandra Meier, Carola Geiler, Zeus Cosmas, Helene Franke, Siyer Roohani, David Wasilewksi, Julia Onken, Peter Vajkoczy, Leonille Schweizer, David Kaul, David Cappe. Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas. Acta neuropathologica communications. vol 12. issue 1. 2024-05-09. PMID:38720399. |
grade 2 meningioma patients treated at our institution were re-classified using an integrated risk stratification involving dna methylation array-based data, copy number assessment and tert promoter mutation analyses. |
2024-05-09 |
2024-05-27 |
Not clear |
| Veronica Aran, Renan Lyra Miranda, Manoela Heringer, Anna Carolina Carvalho da Fonseca, Felipe Andreiuolo, Leila Chimelli, Sylvie Devalle, Paulo Niemeyer Filho, Vivaldo Moura-Net. Liquid biopsy evaluation of circulating tumor DNA, miRNAs, and cytokines in meningioma patients. Frontiers in neurology. vol 14. 2024-01-23. PMID:38259646. |
the world health organization (who) classifies meningiomas based on tumor grades and molecular alterations in genes such as in nf2, akt1, traf7, smo, pik3ca, klf4, smarce1, bap1, h3k27me3, tert promoter, and cdkn2a/b. |
2024-01-23 |
2024-01-25 |
Not clear |
| Burak Han Akkurt, Dorothee Cäcilia Spille, Susanne Peetz-Dienhart, Nora Maren Kiolbassa, Christian Mawrin, Manfred Musigmann, Walter Leonhard Heindel, Werner Paulus, Walter Stummer, Manoj Mannil, Benjamin Brokinke. Radiomics-Based Prediction of TERT Promotor Mutations in Intracranial High-Grade Meningiomas. Cancers. vol 15. issue 17. 2023-09-09. PMID:37686690. |
radiomics-based prediction of tert promotor mutations in intracranial high-grade meningiomas. |
2023-09-09 |
2023-10-07 |
Not clear |
| Burak Han Akkurt, Dorothee Cäcilia Spille, Susanne Peetz-Dienhart, Nora Maren Kiolbassa, Christian Mawrin, Manfred Musigmann, Walter Leonhard Heindel, Werner Paulus, Walter Stummer, Manoj Mannil, Benjamin Brokinke. Radiomics-Based Prediction of TERT Promotor Mutations in Intracranial High-Grade Meningiomas. Cancers. vol 15. issue 17. 2023-09-09. PMID:37686690. |
in meningiomas, tert promotor mutations are rare but qualify the diagnosis of anaplasia, directly impacting adjuvant therapy. |
2023-09-09 |
2023-10-07 |
Not clear |
| Tathiane M Malta, James Snyder, Houtan Noushmehr, Ana Valeria Castr. Advances in Central Nervous System Tumor Classification. Advances in experimental medicine and biology. vol 1416. 2023-07-11. PMID:37432624. |
meningiomas are heterogeneous tumors as depicted by the current 15 distinct variants defined by histology in the 2021 who classification, which also incorporated the first moelcular critiera for meningioma grading: homozygous loss of cdkn2a/b and tert promoter mutation as criteria for a who grade 3 meningioma. |
2023-07-11 |
2023-08-14 |
Not clear |
| A Biczok, J Thorsteinsdottir, P Karschnia, V C Ruf, J C Tonn, J Herms, C Schichor, M M Dorostka. Mutational signature of extracranial meningioma metastases and their respective primary tumors. Acta neuropathologica communications. vol 11. issue 1. 2023-01-14. PMID:36641486. |
only one of four showed cdkn2a homozygous deletion; none showed tert promotor mutation.our results molecularly confirm true metastatic disease in four meningioma patients. |
2023-01-14 |
2023-08-14 |
Not clear |
| So Yeon Won, Jun Ho Lee, Narae Lee, Yae Won Park, Sung Soo Ahn, Jinna Kim, Jong Hee Chang, Se Hoon Kim, Seung-Koo Le. Three-dimensional fractal dimension and lacunarity features may noninvasively predict TERT promoter mutation status in grade 2 meningiomas. PloS one. vol 17. issue 10. 2022-10-20. PMID:36264940. |
three-dimensional fractal dimension and lacunarity features may noninvasively predict tert promoter mutation status in grade 2 meningiomas. |
2022-10-20 |
2023-08-14 |
Not clear |
| Ho-Keung Ng, Kay Ka-Wai Li, Nellie Yuk-Fei Chung, Janice Yuen-Tung Chan, Manix Fung-Man Poon, Queenie Hoi-Wing Wong, Johnny Sheung-Him Kwan, Wai-Sang Poon, Hong Chen, Danny Tat-Ming Chan, Zhi-Feng Shi, Ying Ma. Molecular landscapes of longitudinal NF2/22q and non-NF2/22q meningiomas show different life histories. Brain pathology (Zurich, Switzerland). 2022-09-27. PMID:36167400. |
we studied 99 primary and recurrent meningiomas from 42 patients by fish for 22q, 1q, 1p, 3p, 5q, 6q, 10p, 10q, 14q, 18q, cdkn2a/b homozygous deletion, alt (alternative lengthening of telomere), tert re-arrangement, targeted sequencing and tertp sequencing. |
2022-09-27 |
2023-08-14 |
Not clear |
| Atsushi Okano, Satoru Miyawaki, Yu Teranishi, Kenta Ohara, Hiroki Hongo, Yu Sakai, Daiichiro Ishigami, Hirofumi Nakatomi, Nobuhito Sait. Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review. Neurologia medico-chirurgica. 2022-07-24. PMID:35871574. |
cdkn2a/b homozygous deletion and tert promoter mutations are independent prognostic factors for who grade 3 meningiomas. |
2022-07-24 |
2023-08-14 |
Not clear |
| Elena V Daoud, Kelsey Zhu, Bruce Mickey, Hussein Mohamed, Mandisa Wen, Michael Delorenzo, Ivy Tran, Jonathan Serrano, Kimmo J Hatanpaa, Jack M Raisanen, Matija Snuderl, Chunyu Ca. Epigenetic and genomic profiling of chordoid meningioma: implications for clinical management. Acta neuropathologica communications. vol 10. issue 1. 2022-04-20. PMID:35440040. |
chordoid meningiomas were enriched in mutations in chromatin remodeling genes ep400 (8/11,73%) kmt2c (4/11, 36%) and kmt2d (4/11, 36%), and showed low or absent nf2, tert, smo, and akt1 mutations. |
2022-04-20 |
2023-08-13 |
Not clear |
| Tomoyuki Nakano, Kenji Fujimoto, Arata Tomiyama, Masamichi Takahashi, Takamune Achiha, Hideyuki Arita, Daisuke Kawauchi, Mami Yasukawa, Kenkichi Masutomi, Akihide Kondo, Yoshitaka Narita, Taketoshi Maehara, Koichi Ichimur. Eribulin prolongs survival in an orthotopic xenograft mouse model of malignant meningioma. Cancer science. 2021-12-09. PMID:34839570. |
this study investigated the anti-tumor effect of eribulin against tert promoter mutation-harboring human malignant meningioma cell lines in vitro and in vivo. |
2021-12-09 |
2023-08-13 |
mouse |
| Christian Mirian, Kathrine Grell, Tareq A Juratli, Felix Sahm, Sabine Spiegl-Kreinecker, Matthieu Peyre, Annamaria Biczok, Jörg-Christian Tonn, Stéphane Goutagny, Luca Bertero, Andrea Daniela Maier, Lasse Rehné Jensen, Gabriele Schackert, Helle Broholm, David Scheie, Daniel P Cahill, Priscilla K Brastianos, Jane Skjøth-Rasmussen, Kåre Fugleholm, Morten Ziebell, Tina Nørgaard Munch, Bjarne Winther Kristensen, Tiit Mathiese. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma. Neuropathology and applied neurobiology. 2021-12-01. PMID:34799864. |
implementation of tert promoter mutations improve prognostication of the who classification in meningioma. |
2021-12-01 |
2023-08-13 |
Not clear |
| Christian Mirian, Kathrine Grell, Tareq A Juratli, Felix Sahm, Sabine Spiegl-Kreinecker, Matthieu Peyre, Annamaria Biczok, Jörg-Christian Tonn, Stéphane Goutagny, Luca Bertero, Andrea Daniela Maier, Lasse Rehné Jensen, Gabriele Schackert, Helle Broholm, David Scheie, Daniel P Cahill, Priscilla K Brastianos, Jane Skjøth-Rasmussen, Kåre Fugleholm, Morten Ziebell, Tina Nørgaard Munch, Bjarne Winther Kristensen, Tiit Mathiese. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma. Neuropathology and applied neurobiology. 2021-12-01. PMID:34799864. |
tert promoter mutations have been associated with increased risk of recurrence in meningioma cohorts, thus a potential biomarker for aggressive phenotypes. |
2021-12-01 |
2023-08-13 |
Not clear |
| Ilaria Maggio, Enrico Franceschi, Vincenzo Di Nunno, Lidia Gatto, Alicia Tosoni, Daniele Angelini, Stefania Bartolini, Raffaele Lodi, Alba Ariela Brande. Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. Diagnostics (Basel, Switzerland). vol 11. issue 10. 2021-10-26. PMID:34679551. |
in higher grade meningiomas, mutations of tert promoter and deletion of cdkn2a/b seem to have a prognostic value. |
2021-10-26 |
2023-08-13 |
Not clear |
| Marta Mellai, Omar Porrini Prandini, Aurora Mustaccia, Valentina Fogazzi, Marta Allesina, Marco Krengli, Renzo Boldorin. Human TERT Promoter Mutations in Atypical and Anaplastic Meningiomas. Diagnostics (Basel, Switzerland). vol 11. issue 9. 2021-10-01. PMID:34573966. |
human tert promoter mutations in atypical and anaplastic meningiomas. |
2021-10-01 |
2023-08-13 |
human |
| Andrea Daniela Maier, Adam Stenman, Fredrika Svahn, Christian Mirian, Jiri Bartek, Marianne Juhler, Jan Zedenius, Helle Broholm, Tiit Mathiese. TERT promoter mutations in primary and secondary WHO grade III meningioma. Brain pathology (Zurich, Switzerland). vol 31. issue 1. 2021-09-04. PMID:32805769. |
tert promoter mutations in primary and secondary who grade iii meningioma. |
2021-09-04 |
2023-08-13 |
Not clear |
| Ilah Shin, Yae Won Park, Sung Soo Ahn, Seok-Gu Kang, Jong Hee Chang, Se Hoon Kim, Seung-Koo Le. Clinical and diffusion parameters may noninvasively predict TERT promoter mutation status in grade II meningiomas. Journal of neuroradiology = Journal de neuroradiologie. 2021-03-19. PMID:33716047. |
clinical and diffusion parameters may noninvasively predict tert promoter mutation status in grade ii meningiomas. |
2021-03-19 |
2023-08-13 |
Not clear |